Ny miljonsatsning på life science i Sverige

7,7 miljoner kronor ska nu satsas på ett projekt för att underlätta identifiering och produktion av läkemedel. Bridge Sweden är namnet på projektet och är ett s...

Large study on milk: Risky for women but not for men

The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while n...

Xbrane enters licensing agreement with Indian generics giant

Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.

MSD satsar på peptider i tablettform – ingår licensavtal

MSD kan vara på väg att omvandla några av sina peptidbaserade läkemedel till tablettform. Bolaget har ingått ett licensavtal med österrikiska drug delivery-bola...

New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...

Novo Nordisk to invest billions in new quality control lab

Novo Nordisk has announced plans to invest 2.9 billion Danish kroner in order to establish a new quality control laboratory in Hillerød in northern Zealand, Denmark.

Trends and overview: ELRIG "Robotics and Automation"

Laboratories on the way to end-to-end automation: Robotics, artificial intelligence and automation technology boosted by pandemic

600 million SEK for life science - "Should not be the country of moderation"

Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.

Scientific Solutions

RegSmart Life Science AB

WuXi AppTec, UK Ltd

Novo Nordisk establishes new factory in Denmark

Novo Nordisk establishes a new production facility in Odense, Denmark, an investment of 8.5 billion Danish kroner.

Medicon Valley Alliance

Mercodia AB

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

Astra Zeneca i exklusivt licensavtal med Alteogen

Astra Zenecas dotterbolag ingår ett ett exklusivt licensavtal med det sydkoreanska bolaget Alteogen. Målet är att utveckla subkutana behandlingsalternativ för cancerpatienter.

Truly Labs AB

Galderma

Aurevia

SGS Fimko Ltd.

JMP Statistical Discovery

QPS Netherlands B.V

Prövning av pillervaccin mot covid-19 avbryts i USA

Det amerikanska hälsodepartementet har beordrat stopp för en statligt finansierad fas IIb-studie som skulle utvärdera ett potentiellt pillervaccin mot covid-19.

ZEISS Insights: Measurement of bone plates and screws

Get free access to technical paper.